| section Home
Production, Amateur Radio amateur Model aircraft, rocket- Useful, entertaining |
Stealth master
Electronics Physics Technologies invention |
space Mystery
Earth Mysteries Secrets of the Ocean Stealth section Map |
  |
| Use of material is permitted for reference (for websites - hyperlinks) | |||
Navigation: => |
Home / Products Patents / In the section of the catalog / back / |
|
INVENTION
Russian Federation Patent RU2009509
FORECASTING METHOD psoriasis
Name of the inventor: Filimonkova NN
The name of the patentee: Sverdlovsk Research Institute for Skin and Venereal Diseases
Address for correspondence:
Starting date of the patent: 1991.04.29
Use: medicine, dermatology. SUMMARY OF THE INVENTION: determining enzyme phospholipase A 2 activity in hemolysate of red blood cells and plasma and blood of the patient in excess of performance 2-fold or more relative to the norm predict early relapse. The positive effect: simplifying forecasting process, reduce research time by 2.5 times, while maintaining 100% accuracy of the forecast.
DESCRIPTION OF THE INVENTION
The invention relates to medicine, dermatology, in particular to laboratory methods for predicting the flow of psoriasis.
There is a method for predicting the course of psoriasis by examining the blood of the patient, based on the determination of cytotoxic lymphocyte activity lysed sheep erythrocytes in a period expressed exacerbation of psoriatic process.
The disadvantages of this method are its complexity and the duration of the study (approximately 8 hours).
The purpose of the invention - the acceleration and simplification of the process of psoriasis prediction.
This goal is achieved by research activity of the enzyme phospholipase A 2 in hemolysate of red blood cells and the blood serum of the patient and analysis of the indicators. Exceeding performance 2-fold or more relative to the norm predict early relapse (within 4-8 months.). If the value parameters in the normal range predict remission of disease (by 10 months. Or more) (see. Table).
The method is as follows
Blood is taken from the cubital vein of 5 mL, then 0.5 mL of 10 times diluted (1: 10 saline) heparin. PLA2 enzyme activity in the hemolysate of erythrocytes and blood plasma is determined by the method Tuzhilin SA, Salween AI serum was incubated for 15 min at 60 ° C, then added to 1 ml 1 ml 1% trypsin solution and incubated for 1 hour at 0 C. to 1 ml of the incubation mixture was added 2 ml of working substrate solution and incubated at 37 ° C for 1 h. Then 1 ml of calcium chloride solution to terminate the reaction and titrated with 0.1N. NaOH in the presence of phenolphthalein. The procedure takes about 3 hours. The calculation is made according to the formula 
phospholipase A 2 in 1 ml of blood serum. The definition of this indicator is carried out before and after treatment, and in the process of follow-up of patients. Thinning term remission on the basis of the data obtained will allow to extend his appointment of anti-therapy course.
Example 1. Patient P., 40 years. Diagnosis - psoriatic erythroderma. During an exacerbation indicators LAF process 2 0.62 hemolysate of red blood cells; plasma - 3.0. After 3 weeks on the background of the apparent regression of psoriatic process after the course fotohimioterarii (FHT) figures were respectively 0.22 and 1.71. remission period lasts 18 months.
Example 2. Patient B., 34 years old. The diagnosis - a common vulgar krupnoblyashechny psoriasis, progressive stage. Until indicators LAF destination therapy 2 - 0.41 and 3.2. As a result, the integrated phototherapy indicators LAF activity normalized 2 (respectively 0.17 and 1.6). The subsequent period of remission lasts 13 months.
Example 3. Patient S., 35 years old. The diagnosis - a common vulgar papular, plaque psoriasis, the stationary phase; concomitant cholelithiasis.
Prior to his appointment FHT value of PLA2 in hemolysate of red blood cells and plasma were respectively 0.38 and 2.8. After treatment on the background of clinical recovery indicators have reached 0.50 and 3.0, respectively. remission period lasted for 6 months. And then began a sharp aggravation of the process. Preventive treatment district doctor was not carried out.
Example 4. Patient P., 50 years. The diagnosis - a total psoriatic erythroderma, torpid course.
Initial indicators LAF activity of 2 - 0.92 and 1.96. Against the backdrop of ongoing FHT 3 weeks figures were 0.41 and 3.33. Upon reaching the remission period 6 months. a course of anti-traditional therapy, which allowed to extend the period of remission up to 10 months.
Thus, the proposed method allows a fast and affordable (in comparison with the prototype), up to 100% predict the further course of psoriatic process in cases of possible recurrence, through timely preventive treatment, to influence the course of the disease. (56) Author's certificate USSR N 1263250, cl. G 61 K 39/00.
CLAIM
A method of predicting psoriasis by blood tests of the patient, characterized in that, in order to simplify the process explore the activity fisfolipazy A 2 in the erythrocytes and blood plasma before and after treatment and at higher rates after treatment with 2-fold or more relative to the norm, predict early relapse.
print version
Publication date 01.04.2007gg
Comments
Commenting, keep in mind that the content and the tone of your messages can hurt the feelings of real people, show respect and tolerance to his interlocutors, even if you do not share their opinion, your behavior in terms of freedom of speech and anonymity offered by the Internet, is changing not only virtual, but real world. All comments are hidden from the index, spam control.